JPWO2021170068A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021170068A5
JPWO2021170068A5 JP2022551742A JP2022551742A JPWO2021170068A5 JP WO2021170068 A5 JPWO2021170068 A5 JP WO2021170068A5 JP 2022551742 A JP2022551742 A JP 2022551742A JP 2022551742 A JP2022551742 A JP 2022551742A JP WO2021170068 A5 JPWO2021170068 A5 JP WO2021170068A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr3
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022551742A
Other languages
English (en)
Japanese (ja)
Other versions
JP7702961B6 (ja
JP7702961B2 (ja
JP2023516004A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/078051 external-priority patent/WO2021170068A1/en
Publication of JP2023516004A publication Critical patent/JP2023516004A/ja
Publication of JPWO2021170068A5 publication Critical patent/JPWO2021170068A5/ja
Application granted granted Critical
Publication of JP7702961B2 publication Critical patent/JP7702961B2/ja
Publication of JP7702961B6 publication Critical patent/JP7702961B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022551742A 2020-02-28 2021-02-26 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用 Active JP7702961B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/077148 2020-02-28
CN2020077148 2020-02-28
PCT/CN2021/078051 WO2021170068A1 (en) 2020-02-28 2021-02-26 Anti-cd137 constructs, multispecific antibody and uses thereof

Publications (4)

Publication Number Publication Date
JP2023516004A JP2023516004A (ja) 2023-04-17
JPWO2021170068A5 true JPWO2021170068A5 (enrdf_load_stackoverflow) 2024-02-27
JP7702961B2 JP7702961B2 (ja) 2025-07-04
JP7702961B6 JP7702961B6 (ja) 2025-07-17

Family

ID=77489868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551742A Active JP7702961B6 (ja) 2020-02-28 2021-02-26 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用

Country Status (9)

Country Link
US (1) US20230067770A1 (enrdf_load_stackoverflow)
EP (1) EP4110827A4 (enrdf_load_stackoverflow)
JP (1) JP7702961B6 (enrdf_load_stackoverflow)
KR (1) KR20220148228A (enrdf_load_stackoverflow)
CN (1) CN115190889A (enrdf_load_stackoverflow)
AU (1) AU2021228077A1 (enrdf_load_stackoverflow)
CA (1) CA3169943A1 (enrdf_load_stackoverflow)
WO (1) WO2021170068A1 (enrdf_load_stackoverflow)
ZA (1) ZA202210626B (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001329A2 (pt) * 2019-07-26 2022-03-22 Abl Bio Inc Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
KR20240000505A (ko) * 2021-04-23 2024-01-02 상하이 헨리우스 바이오테크, 인크. 항gpc3 항체, 다중 특이적 항체 및 사용 방법
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025101526A1 (en) * 2023-11-06 2025-05-15 Beijing Starmab Biomed Technology Ltd Multi-specific cancer-targeting antibodies
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
PL2614082T3 (pl) * 2010-09-09 2019-02-28 Pfizer Inc. Cząsteczki wiążące 4-1BB
US10584171B2 (en) * 2014-05-30 2020-03-10 Henlix Biotech Co., Ltd. Anti-epidermal growth factor receptor (EGFR) antibodies
US20190169308A1 (en) 2016-04-22 2019-06-06 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
EP3470428A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof

Similar Documents

Publication Publication Date Title
US11999801B2 (en) Multispecific antibodies
CN103068846B9 (zh) 包含二硫键稳定性Fv片段的双特异性抗体
JP2021098733A5 (enrdf_load_stackoverflow)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
Xiong et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody
JP2020533311A5 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
JPWO2019129221A5 (enrdf_load_stackoverflow)
US20220002398A1 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
WO2010112194A1 (en) Antigen-binding polypeptides and multispecific antibodies comprising them
MX2011010159A (es) Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
CN102369214A (zh) 三价、双特异性抗体
JP2020502233A5 (enrdf_load_stackoverflow)
JPWO2020033587A5 (enrdf_load_stackoverflow)
JPWO2021170068A5 (enrdf_load_stackoverflow)
JPWO2020033664A5 (enrdf_load_stackoverflow)
JPWO2019217332A5 (enrdf_load_stackoverflow)
JPWO2021170071A5 (enrdf_load_stackoverflow)
JPWO2022067262A5 (enrdf_load_stackoverflow)
JPWO2021116337A5 (enrdf_load_stackoverflow)
JPWO2022104236A5 (enrdf_load_stackoverflow)
JPWO2021247769A5 (enrdf_load_stackoverflow)
CA3170141A1 (en) Antigen-binding molecules against alppl2 and/or alpp and uses thereof
JPWO2020102555A5 (enrdf_load_stackoverflow)
JPWO2022159984A5 (enrdf_load_stackoverflow)